225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients in highly challenging clinical situations who showed a complete response to 225Ac-PSMA-617 therapy. Methods:68Ga-PSMA-11 PET/CT validated the presence of the PSMA-positive tumor phenotype. A 100-kBq activity of 225Ac-PSMA-617 per kilogram of body weight was administered bimonthly. Prostate-specific antigen response and hematologic toxicity were measured at least every 4 wk. Restaging was performed with 68Ga-PSMA-11 PET/CT. Results: Both patients experienced a prostate-specific antigen decline to below the measurable level and showed a complete response on imaging. No relevant hematologic toxicity was observed. Xerostomia was the only mentionable clinical side effect. Conclusion: Targeted α-therapy with 225Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage prostate cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Afshar-Oromieh, A., Avtzi, E., Giesel, F. L., Holland-Letz, T., Linhart, H. G., Eder, M., Eisenhut, M., Boxler, S., Hadaschik, B. A., Kratochwil, C., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2949-6 · Cited by 964
Self-citationKratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Self-citationBenešová, M., Schäfer, M., Bauder-Wüst, U., Afshar-Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147413 · Cited by 612
Self-citationSgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552 · cited 1×
“In this setting, targeted a-therapy can be beneficial because the 50- to 100-mm range of an a-particle (2–3 cell diameters) translates into a much more cell-specific radiotherapy (11).”
BackgroundTumor therapy with targeted atomic nanogenerators.
McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., et al. (2001) · Science · doi:10.1126/science.1064126 · Cited by 501
Targeted α particle immunotherapy for myeloid leukemia
Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, Å. M., Hamacher, K. A., Ma, D., Humm, J. L., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1233.h81602001233_1233_1239 · Cited by 472
Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R., Murphy, K., Haberkorn, U., & Morgenstern, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2857-9 · Cited by 407
Self-citationDelker, A., Fendler, W. P., Kratochwil, C., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., Tritschler, S., Stief, C. G., Kopka, K., Haberkorn, U., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3174-7 · Cited by 322 · cited 3×
“Nevertheless, about 30% of patients do not respond to 177Lu-labeled PSMA ligands, and despite good tolerability in general, diffuse red marrow infiltration has been suggested as a risk factor for developing relevant hematologic toxicity (4).”
BackgroundMethodSelf-citationAhmadzadehfar, H., Eppard, E., Kürpig, S., Fimmers, R., Yordanova, A., Schlenkhoff, C. D., Gärtner, F., Rogenhofer, S., & Essler, M. (2016) · Oncotarget · doi:10.18632/oncotarget.7245 · Cited by 282
Benešová, M., Bauder-Wüst, U., Schäfer, M., Klika, K. D., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01210 · Cited by 228
Self-citation
Cited by
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 963
Giesel, F. L., Hadaschik, B., Cardinale, J., Radtke, J., Vinsensia, M., Lehnert, W., Kesch, C., Tolstov, Y., Singer, S., Grabe, N., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3573-4 · Cited by 592
Self-citationKratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505
“The labeling conditions and imaging protocols for 68Ga-PSMA-11 (19), 99mTc- MIP1427 (1) and post-therapeutic 225Ac-PSMA-617 emission scans (20) have been described previously.”
BackgroundSelf-citationViolet, J., Jackson, P., Ferdinandus, J., Sandhu, S., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Thang, S. P., Eu, P., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219352 · Cited by 504
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
Kostelnik, T. I., & Orvig, C. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 483
Nuhn, P., De Bono, J. S., Fizazi, K., Freedland, S. J., Grilli, M., Kantoff, P. W., Sonpavde, G., Sternberg, C. N., Yegnasubramanian, S., & Antonarakis, E. S. (2019) · European Urology · doi:10.1016/j.eururo.2018.03.028 · Cited by 437
Kratochwil, C., Bruchertseifer, F., Rathke, H., Hohenfellner, M., Giesel, F. L., Haberkorn, U., & Morgenstern, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203539 · Cited by 421
Self-citationAn Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M., Krolicki, L., & Bruchertseifer, F. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180502104524 · Cited by 370
Self-citation225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
Sathekge, M., Bruchertseifer, F., Knoesen, O., Reyneke, F., Lawal, I., Lengana, T., Davis, C., Mahapane, J., Corbett, C., Vorster, M., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4167-0 · Cited by 354
Self-citationPotent candidates for Targeted Auger Therapy: Production and radiochemical considerations
Filosofov, D., Kurakina, E., & Radchenko, V. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.12.001 · Cited by 341
Emmett, L., Willowson, K., Violet, J., Shin, J., Blanksby, A., & Lee, J. (2017) · Journal of Medical Radiation Sciences · doi:10.1002/jmrs.227 · Cited by 305
Radiolabelling of nanomaterials for medical imaging and therapy
Pellico, J., Gawne, P. J., & T. M. de Rosales, R. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00384k · Cited by 304
Watabe, T., Liu, Y., Kaneda-Nakashima, K., Shirakami, Y., Lindner, T., Ooe, K., Toyoshima, A., Nagata, K., Shimosegawa, E., Haberkorn, U., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233122 · Cited by 302
Self-citationHeck, M. M., Tauber, R., Schwaiger, S., Retz, M., D’Alessandria, C., Maurer, T., Gafita, A., Wester, H.-J., Gschwend, J. E., Weber, W. A., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.11.016 · Cited by 298
Feuerecker, B., Tauber, R., Knorr, K., Heck, M., Beheshti, A., Seidl, C., Bruchertseifer, F., Pickhard, A., Gafita, A., Kratochwil, C., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.11.013 · Cited by 277
Self-citationFuture of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
Langbein, T., Weber, W. A., & Eiber, M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.220566 · Cited by 269
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y.-T., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 261
α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 1
Poty, S., Francesconi, L. C., McDevitt, M. R., Morris, M. J., & Lewis, J. S. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186338 · Cited by 256
Khreish, F., Ebert, N., Ries, M., Maus, S., Rosar, F., Bohnenberger, H., Stemler, T., Saar, M., Bartholomä, M., & Ezziddin, S. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04612-0 · Cited by 215
“The production and quality control of [(177)Lu]Lu-PSMA-617 and [(225)Ac]Ac-PSMA-617 was accomplished in analogy to published methodology [2, 11, 12].”
MethodSathekge, M. M., Lawal, I. O., Bal, C., Bruchertseifer, F., Ballal, S., Cardaci, G., Davis, C., Eiber, M., Hekimsoy, T., Knoesen, O., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00638-1 · Cited by 210
Self-citation177Lu-PSMA Radioligand Therapy for Prostate Cancer
Fendler, W. P., Rahbar, K., Herrmann, K., Kratochwil, C., & Eiber, M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191023 · Cited by 206
“a-therapy using 225Ac-labeled PSMA-617 has induced promising response rates in patients whose disease progressed under 223Ra or 177Lu-PSMA treatment (46,47).”
BackgroundSelf-citationTreatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise
Sumanasuriya, S., & De Bono, J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030635 · Cited by 203
“The usage of gallium-PSMA positron-emitting-tomography (PET) may be a useful predictive biomarker for these agents (Kratochwil et al. 2016).”
BackgroundDevelopment of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
Robertson, A. K. H., Ramogida, C. F., Schaffer, P., & Radchenko, V. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180416161908 · Cited by 202
“ca cancers [10-13], the development of these drugs faces many challenges that have slowed progress, including: 1) the limited supply of (225)Ac - currently only 63 GBq (1.”
BackgroundInfluentialTargeted alpha therapy: progress in radionuclide production, radiochemistry, and applications.
Nelson, B. J. B., Andersson, J. D., & Wuest, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010049 · Cited by 194
“Another study outlined how α-particle radiotherapy for metastatic castration resistant prostate cancer using [225Ac]Ac-PSMA-617 was able to overcome resistance to [177Lu]Lu-PSMA617 β−-particle therapy [16].”
BackgroundFirst Clinical Results for PSMA-Targeted α-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients
Zacherl, M. J., Gildehaus, F. J., Mittlmeier, L., Böning, G., Gosewisch, A., Wenter, V., Unterrainer, M., Schmidt-Hegemann, N., Belka, C., Kretschmer, A., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.251017 · Cited by 189
“Targeted alpha therapy (TAT) using 225Ac-PSMA-617 has been introduced with substantial therapeutic efficacy and has the potential to overcome resistance to βemitter therapy (6, 7).”
BackgroundSchuchardt, C., Zhang, J., Kulkarni, H. R., Chen, X., Müller, D., & Baum, R. P. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262713 · Cited by 187
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations
Makvandi, M., Dupis, E., Engle, J. W., Nortier, F. M., Fassbender, M. E., Simon, S., Birnbaum, E. R., Atcher, R. W., John, K. D., Rixe, O., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0550-9 · Cited by 173
“[86] combined (225)Ac with the prostate-specific membrane antigen (PSMA): (225)Ac-PSMA-617.”
BackgroundDevelopment of targeted alpha particle therapy for solid tumors.
Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., et al. (2019) · Molecules · doi:10.3390/molecules24234314 · Cited by 157
“Additional clinical studies have further revealed the remarkable anti-tumor activity and the promising duration of tumor-control of treatment with 225Ac-PSMA-617 [6,59,60].”
BackgroundSupply and clinical application of Actinium-225 and Bismuth-213.
Morgenstern, A., Apostolidis, C., & Bruchertseifer, F. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.02.003 · Cited by 141
The Future of Radioligand Therapy: α, β, or Both?
Haberkorn, U., Giesel, F., Morgenstern, A., & Kratochwil, C. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.190124 · Cited by 88
Self-citationSathekge, M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Knoesen, O., Mahapane, J., Davis, C., Mdlophane, A., Maes, A., Mokoala, K., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263618 · Cited by 81
Self-citationTagawa, S. T., Thomas, C., Sartor, A. O., Sun, M., Stangl-Kremser, J., Bissassar, M., Vallabhajosula, S., Castellanos, S. H., Nauseef, J. T., Sternberg, C. N., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.00573 · Cited by 78
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68
Hooijman, E. L., Chalashkan, Y., Ling, S. W., Kahyargil, F. F., Segbers, M., Bruchertseifer, F., Morgenstern, A., Seimbille, Y., Koolen, S. L. W., Brabander, T., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050715 · Cited by 59
“8 min, ~30 min), a secular equilibrium was formed with Ac-225 (Figure 1) [21].”
BackgroundSelf-citationImaging-guided targeted radionuclide tumor therapy: From concept to clinical translation
Sun, J., Huangfu, Z., Yang, J., Wang, G., Hu, K., Gao, M., & Zhong, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114538 · Cited by 57
The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors
Pruis, I. J., van Dongen, G. A. M. S., & Veldhuijzen van Zanten, S. E. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031029 · Cited by 35
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future
Ayzman, A., Pachynski, R. K., & Reimers, M. A. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01317-5 · Cited by 18
“For example, novel RLTs such as Actinium-225 PSMA-617 are being tested to overcome resistance to Lutetium-based therapies [6, 7].”
A Consensus Time for Performing Quality Control of 225Ac-Labeled Radiopharmaceuticals
Kelly, J. M., Amor-Coarasa, A., Sweeney, E., Wilson, J. J., Causey, P. W., & Babich, J. (2021) · doi:10.21203/rs.3.rs-39342/v2 · Cited by 11
Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands
Naik, M., Khan, S. R., Lewington, V., Challapalli, A., Eccles, A., & Barwick, T. D. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae092 · Cited by 10
Metadata
- Authors
- Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2016-07-07
- Volume
- 57
- Issue
- 12
- Pages
- 1941-1944
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2467018059
- Cited by
- 1,100
- References
- 16
- FWCI
- 60.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.